MBX
NASDAQ HealthcareMBX Biosciences, Inc. - Common Stock
Biotechnology
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
๐ Market Data
| Price | $58.32 |
|---|---|
| Volume | 821,850 |
| Market Cap | 2.78B |
| RSI (14-Day) | 62.6 |
| 200-Day MA | $32.43 |
| 50-Day MA | $41.80 |
| 52-Week High | $66.55 |
| 52-Week Low | $9.63 |
| Forward P/E | -14.84 |
| Price / Book | 6.34 |
๐ฏ Investment Strategy Scores
MBX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (67/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find MBX in your text
Paste any article, transcript, or post โ the tool will extract MBX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.